U.S News. & World Report: Is it allergies or sinusitis? Many folks are misdiagnosed
UC research offers hope for more accurate diagnoses and more effective treatment
New research out of UC examines the incidence of people who are being treated for allergies when they actually have chronic rhinosinusitis (CRS), and the medicines they are taking for their allergy symptoms have little effect. U.S. News & World Report published a report on the research, interviewing the lead author Ahmad Sedaghat, MD, PhD, of the UC College of Medicine.
“We have seen so many patients suffer for so long due to the confusion between allergies and CRS,” said Sedaghat. “I’ve had patients who tell me that they have been treated with allergy shots for 10, 20 or more years without relief of their symptoms but who after we discovered they had CRS and we started them on appropriate treatment, achieved relief within a few months."
Ahmad Sedaghat, MD, PhD, professor of Otolaryngology, Head & Neck Surgery at the UC College of Medicine/Photo/Colleen Kelley/UC Marketing + Brand
CRS affects almost 15% of Americans, according to Sedaghat. The condition is typically treated with antibiotics.
The trouble is, the outward signs of sinusitis can mimic those of a nasal allergy.
“As someone who grew up in [the Midwest], I can attest to how commonly we tend to attribute sinus and nasal symptoms to ‘allergies,'" Sedaghat said. "But the reason for this is that nasal allergies [allergic rhinitis] and CRS have overlapping symptomatology, often characterized by nasal blockage and nasal drainage. Both can also cause sinus pressure."
The treatment for CRS and nasal allergies is very different, however, which means that misdiagnosis can lead to months or years of needless misery.
The new study involved 219 people who'd been thought to have nasal allergies. Each underwent nasal endoscopy and testing to gauge the severity and type of their sinus/nasal symptoms.
“We specifically used this questionnaire to study our patients’ symptoms because we could simultaneously measure symptoms of CRS and allergic rhinitis without having to use different questionnaires,” Sedaghat explained.
A majority (91.5%) did have some form of environmental allergy, testing revealed.
Read more about Sedaghat's research here.
Lead photo/iStock
Next Lives Here
The University of Cincinnati is classified as a Research 1 institution by the Carnegie Commission and is ranked in the National Science Foundation's Top-35 public research universities. UC's graduate students and faculty investigate problems and innovate solutions with real-world impact. Next Lives Here.
Related Stories
2021 University Recognition Ceremony honors student achievements
April 13, 2021
The University of Cincinnati recognizes students each year who have made significant service, leadership, and academic contributions to the UC community. These students exemplify the spirit of what it means to be a Bearcat.
UC Day of Giving a success
April 28, 2021
University of Cincinnati Day of Giving’s 24-hour challenge was a tremendous success this year, raising $2,219,197 with 3,232 gifts. The fourth annual UC Day of Giving raised its most money to date with alumni, donors, students, faculty and staff joining together to support UC and UC Health.
President picks exceptional talent
April 28, 2021
The University of Cincinnati 2021 Presidential Leadership Medal of Excellence Awards honor six undergraduate scholars for scholarship, leadership, character, service and the ideals of the university. Awardees are spotlighted for exceptional academics, creativity, community service and innovation.
Grad students earn president's highest honor
April 28, 2021
The University of Cincinnati 2021 Presidential Medal of Graduate Student Excellence Awards honor three graduate scholars for scholarship, leadership, character, service and the ideals of the university. Awardees are spotlighted for exceptional academics, creativity, community service and innovation.
GIVEHOPE and BSI Engineering Celebrate Ten Years of Driving Research
August 3, 2021
Years after two personal losses from pancreatic cancer, Cincinnati-based nonprofit GIVEHOPE and consulting firm BSI Engineering are celebrating a philanthropic partnership that has funded 13 pilot research projects at the University of Cincinnati Cancer Center.
Finding community and building a future
July 9, 2021
As a University of Cincinnati College of Medicine student, Sarah Appeadu, MD, ’21, remembers journaling on the “3 Cs” that got her through medical school: Community, community, community. Now, when she lists the people who supported her through four years of training—the last year in a global pandemic—it keeps growing: her family, her church, her classmates, and the college’s Office of Student Affairs and Office of Diversity, Equity and Inclusion. “I look back and it was such a crucial time to really be nurtured in that way,” she says. “I’m so thankful that I had those people. It shows being around the right people really mattered. That’s my same hope for residency even.”
New York Times: Flint Weighs Scope of Harm to Children Caused by Lead in Water
February 1, 2016
Kim Dietrich, a professor of environmental health at UC's College of Medicine, is quoted in this story on the medical problems that could develop among the thousands of young children exposed to lead-contaminated water in Flint, Mich.
Cancer-Causing Gene Found in Plasma May Help Predict Outcomes for Patients
February 18, 2016
Researchers at the University of Cincinnati have discovered that a human cancer-causing gene, called DEK, can be detected in the plasma of head and neck cancer patients.
UC Receives $1.9 Million to Study Pain
February 15, 2016
Jun-Ming Zhang, MD, of the UC College of Medicine, is the principal investigator of a $1.95 million grant to study the interacting roles of the sympathetic and sensory nervous and immune systems in back and neuropathic pain models.
MD Magazine: Generic Drug Equally Effective in Epilespy
February 22, 2016
Michael Privitera, MD, a professor of neurology at UC's College of Medicine and director of the Epilepsy Center at the UC Neuroscience Institute, is featured in this story about research he led that examined the efficacy of generic drug substitution for epilepsy.